Compare AstraZeneca plc (AZN) vs Nvidia Corp (NVDA) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

NVIDIA (NVDA) trades at $212.50, up 4.41% today, with a bullish technical signal and strong fundamentals. The stock shows robust revenue growth, with Q1 2026 EPS beating expectations at $1.87 versus $1.76. Valuation ratios like P/E of 32.43 and P/S of 20.44 reflect high investor expectations. Recent news highlights AI-driven growth, with analysts projecting a consensus price target of $325.86. Cash flow from operations surged to $64.09B in 2025, supporting expansion.

Outlook remains positive due to AI leadership and earnings momentum, but risks include competition and market volatility. With 75% analyst buy ratings and institutional confidence, NVDA offers growth potential, though investors should monitor execution risks and macroeconomic factors that could impact performance.